AIF-1 Drives Corneal Neovascularization by Promoting Inflammatory Macrophage Activation via the MAPK and PI3K/AKT/mTOR Signaling Pathways
Investigative Ophthalmology & Visual Science · 2026-02-06 · 67 (2) · 22
DOI: 10.1167/iovs.67.2.22 ↗At a glance
Journal article in Investigative Ophthalmology & Visual Science, published on 2026-02-06. Written by Qinghua Li and 9 co-authors. Institution: State Key Laboratory Cultivation Base, Shandong Key Laboratory of Eye Diseases, Eye Institute of Shandong First Medical University, Qingdao, China. Major MEDLINE topics: Corneal Neovascularization, TOR Serine-Threonine Kinases, Proto-Oncogene Proteins c-akt, Macrophage Activation. Cited 5 times so far (Crossref); 40 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Purpose
This study aims to elucidate the precise mechanisms of allograft inflammatory factor 1 (AIF-1)-mediated inflammatory macrophage activation in corneal neovascularization (CNV) pathogenesis and identify a potential therapeutic target.
Methods
In vitro, RAW 264.7 macrophages were transfected with small interfering RNA (siRNA) targeting AIF-1. Flow cytometry and immunofluorescence were used to detect macrophage polarization, and ELISA was employed to quantify inflammatory cytokines secreted by macrophages. Intracellular reactive oxygen species (ROS) levels were measured using a ROS detection kit. In vivo, a mouse CNV model was established by alkali burns. AIF-1 siRNA was administered via subconjunctival injection. Inflammatory cytokines and angiogenesis-related factors in the cornea were assessed through Western blot (WB), immunohistochemistry, and immunofluorescence. Slit-lamp imaging and histopathologic analysis were conducted to evaluate angiogenesis and inflammation. Phosphorylation levels of proteins in the MAPK and PI3K/AKT/mTOR pathways were examined by WB.
Results
We observed stage-dependent upregulation of AIF-1, paralleled by CNV severity, alongside coordinated overexpression of CD86 and VEGFA. Silencing AIF-1 suppressed inflammatory macrophage activation. AIF-1 promoted macrophage recruitment to the cornea and upregulated TNF-α, IL-1β, IL-6, and VEGFA expression, further exacerbating inflammation, oxidative stress, and angiogenesis in the mouse CNV model. CNV severity was alleviated after AIF-1 inhibition. Notably, AIF-1 drove CNV progression by activating both the MAPK and PI3K/AKT/mTOR signaling pathways.
Conclusions
AIF-1 played a pivotal role in CNV progression. AIF-1 promoted inflammatory macrophage activation, exacerbating corneal inflammation and neovascularization via the MAPK and PI3K/AKT/mTOR signaling pathways, which offers novel insights for CNV treatment.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- State Key Laboratory Cultivation Base, Shandong Key Laboratory of Eye Diseases, Eye Institute of Shandong First Medical University, Qingdao, China.
- Eye Hospital of Shandong First Medical University (Shandong Eye Hospital), Jinan, China.
- School of Ophthalmology, Shandong First Medical University, Jinan, China.
Cite
APA
Li, Q., Bao, Q., Wei, C., Xie, Y., Zhao, S., Yan, H., Wu, F., Li, W., Liu, X., & Gao, H. (2026). AIF-1 Drives Corneal Neovascularization by Promoting Inflammatory Macrophage Activation via the MAPK and PI3K/AKT/mTOR Signaling Pathways. Investigative Ophthalmology & Visual Science, 67(2), 22. https://doi.org/10.1167/iovs.67.2.22
Vancouver
Li Q, Bao Q, Wei C, Xie Y, Zhao S, Yan H, et al. AIF-1 Drives Corneal Neovascularization by Promoting Inflammatory Macrophage Activation via the MAPK and PI3K/AKT/mTOR Signaling Pathways. Investigative Ophthalmology & Visual Science. 2026;67(2):22. doi:10.1167/iovs.67.2.22
BibTeX
@article{Li2026,
author = {Li, Qinghua and Bao, Qingdong and Wei, Chaoqun and Xie, Yanshuo and Zhao, Sihan and Yan, Hui and Wu, Fan and Li, Wenlong and Liu, Xiaoxue and Gao, Hua},
title = {AIF-1 Drives Corneal Neovascularization by Promoting Inflammatory Macrophage Activation via the MAPK and PI3K/AKT/mTOR Signaling Pathways},
journal = {Investigative Ophthalmology & Visual Science},
year = {2026},
volume = {67},
number = {2},
pages = {22},
doi = {10.1167/iovs.67.2.22}
}
EUVIMED